問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2021-09-22 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2024-11-01 - 2028-12-31

Phase II

Active
A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Mirivadelgat, an Aldehyde Dehydrogenase 2 Activator, in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Condition/Disease

    Group 3 Pulmonary Hypertension

  • Test Drug

    膠囊劑

Participate Sites
9Sites

Recruiting9Sites

2019-01-01 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-05-01 - 2024-04-29

Phase II

Completed
A Phase Ⅱ,Double-blind,Randomized,Controlled Study to Evaluate the Safety and Efficacy of Silmitasertib(CX-4945) in Hospitalized Adults with COVID-19

  • Condition/Disease

    Community-acquired Pneumonia 、SARS-CoV-2 -Associated Pneumonia 、Influenza With Pneumonia

  • Test Drug

    CX-4945

Participate Sites
1Sites

Recruiting1Sites

2020-10-07 - 2022-06-30

Phase II

Completed
A Randomized, Multicenter, Open-Label, Two-Arm, Phase II, Neoadjuvant Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    GDC-9545 Palbociclib Anastrozole

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2023-10-31 - 2027-08-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Regorafenib Keytruda injection/Keytruda

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2026-03-01 - 2028-02-29

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

2021-12-30 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-09-23 - 2028-02-13

Phase II

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic hepatitis B virus (HBV) infection

  • Test Drug

    Film-coated tablet Film-coated tablet

Participate Sites
8Sites

Recruiting8Sites

2021-02-26 - 2025-12-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 27 28 29 30 31 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB